Convalescent plasma offers a ‘blueprint’ for future pandemics
Hopkins researchers help secure full FDA approval to treat immunocompromised COVID-19 patients—paving the way to explore using convalescent plasma during future infectious disease outbreaks, epidemics, and pandemics